Holen Sie sich die Stockscreener-App
4.20
2.69%
0.11
Schlusskurs vom Vortag:
$4.09
Offen:
$4.17
24-Stunden-Volumen:
16.02M
Relative Volume:
0.40
Marktkapitalisierung:
$2.19B
Einnahmen:
$64.60M
Nettoeinkommen (Verlust:
$-377.75M
KGV:
-2.7097
EPS:
-1.55
Netto-Cashflow:
$-335.64M
1W Leistung:
-1.18%
1M Leistung:
-2.78%
6M Leistung:
-19.39%
1J Leistung:
-41.75%
1-Tages-Spanne:
$4.12
$4.23
1-Wochen-Bereich:
$4.05
$4.31
52-Wochen-Spanne:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Firmenname
Recursion Pharmaceuticals Inc
Sektor
Branche
Telefon
(385) 269-0203
Adresse
41S RIO GRANDE STREET, SALT LAKE CITY
Vergleichen Sie RXRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
4.20 | 2.13B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-03-16 | Eingeleitet | Needham | Buy |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-04 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | Eingeleitet | Berenberg | Buy |
| 2021-05-11 | Eingeleitet | BofA Securities | Buy |
| 2021-05-11 | Eingeleitet | Goldman | Neutral |
| 2021-05-11 | Eingeleitet | JP Morgan | Neutral |
| 2021-05-11 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Recursion Pharmaceuticals Inc Aktie (RXRX) Neueste Nachrichten
Recursion Pharmaceuticals Stock (RXRX) Opinions on Analyst Upgrade and Insider Trading - Quiver Quantitative
Here’s What J.P. Morgan Thinks About Recursion Pharmaceuticals (RXRX) - Insider Monkey
JPMorgan boosts rating on Recursion Pharmaceuticals (RXRX) amid AI-driven drug pipeline - MSN
JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline - Insider Monkey
Bank Pictet & Cie Europe AG Acquires Shares of 1,630,000 Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
Recursion Pharmaceuticals reports positive Phase 1b/2 TUPELO trial results, validating AI-driven therapy for FAP - MSN
Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. - Finviz
Cathie Wood’s ARK Investment buys 755K shares of Recursion Pharmaceuticals, Inc. (RXRX) - MSN
Cathie Wood’s ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. (RXRX) - Insider Monkey
Cathie Wood's ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. (RXRX) - Finviz
Recursion Pharmaceuticals (NASDAQ:RXRX) CFO Ben Taylor Sells 21,383 Shares - MarketBeat
Taylor, CFO of Recursion Pharmaceuticals, sells $89k in shares By Investing.com - Investing.com UK
Taylor, CFO of Recursion Pharmaceuticals, sells $89k in shares - Investing.com
RXRX Stock Today: Insider Selling, CEO Transition and Trial Catalyst Shape Recursion Pharmaceuticals’ Outlook (December 2025) - ts2.tech
Best Biotech Stocks To Follow NowDecember 26th - MarketBeat
Recursion Pharmaceuticals (NASDAQ:RXRX) Insider Najat Khan Sells 124,403 Shares - MarketBeat
RXRX Stock Plummet: Here’s What’s Happening - timothysykes.com
Recursion Pharmaceuticals Reports Positive Phase 1b/2 TUPELO Trial Results, Validating AI-Driven Therapy for FAP - Insider Monkey
10 AI Stocks Under $20 to Buy Now - Insider Monkey
Recursion Pharmaceuticals Rises as Positive Phase 1b/2 Trial Results for REC-4881 Validate AI-Driven Drug Discovery Platform - Finviz
Cathie Wood is doubling down on Recursion Pharmaceuticals stock. Should you buy RXRX here? - MSN
Recursion Pharmaceuticals Stock (RXRX) Opinions on Analyst Upgrade and Clinical Data - Quiver Quantitative
Growth or Bubble? Decoding Recursion Pharmaceuticals’ Stock Surge - timothysykes.com
3 Small AI Plays to Buy for 2026 - Sahm
Is Recursion Pharmaceuticals, Inc. (RXRX) the best fundamentally strong penny stock to buy? - MSN
Is Recursion (RXRX) Finally Proving Its AI Drug Discovery Model With REC-4881’s Early Data? - simplywall.st
Recursion Pharmaceuticals (RXRX) Stock News Today: Analysts Refocus on REC-4881 Data, ARK Buying, and a 2026 CEO Transition - ts2.tech
Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here? - Barchart.com
Top Biotech Stocks To ResearchDecember 17th - MarketBeat
How Investors May Respond To Recursion Pharmaceuticals (RXRX) Early FAP Trial Success And AI Platform Validation - Yahoo Finance
Is Recursion Pharmaceuticals Inc. stock overvalued by current metricsJuly 2025 Market Mood & High Accuracy Trade Alerts - Bölüm Sonu Canavarı
Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock - AOL.com
Recursion Pharmaceuticals (RXRX): Valuation Check After Encouraging TUPELO Trial Data and Analyst Upgrades - Yahoo Finance
Aug Retail: Will Recursion Pharmaceuticals Inc stock gain from lower inflationMarket Volume Summary & Daily Profit Maximizing Trade Tips - moha.gov.vn
Is Recursion Pharmaceuticals, Inc. (RXRX) the Best Fundamentally Strong Penny Stock to Buy? - Insider Monkey
Recursion Pharmaceuticals RXRX Stock News and Forecasts on December 21 2025 - ts2.tech
Recursion Pharmaceuticals (RXRX) Price Target Increased by 10.53% to 7.14 - Nasdaq
Is Recursion Pharmaceuticals Inc. stock a safe buy before earningsJuly 2025 Macro Moves & Free Real-Time Volume Trigger Notifications - Улправда
Recursion Pharmaceuticals Stock (RXRX) News and Forecasts for Dec. 20, 2025: TUPELO Trial Data, JPMorgan Upgrade, and What Comes Next - ts2.tech
Published on: 2025-12-19 22:42:25 - Улправда
CEO Gibson Files To Sell 40,000 Of Recursion Pharmaceuticals Inc [RXRX] - TradingView — Track All Markets
Will Recursion Pharmaceuticals Inc. stock benefit from green energy trends2025 Trading Recap & AI Based Trade Execution Alerts - DonanımHaber
Finanzdaten der Recursion Pharmaceuticals Inc-Aktie (RXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Recursion Pharmaceuticals Inc-Aktie (RXRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Khan Najat | Chief R&D Commercial Officer |
Dec 22 '25 |
Sale |
4.41 |
124,403 |
548,592 |
611,135 |
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):